
Ash 2021 preview – small increases and big falls
The early movers could point to a disappointing meeting.

Second-quarter catalysts for the smaller players
Key catalysts approach for Orphazyme, Gemini and Immutep.

Ash 2020 movers – shorts roasting on an open fire
IGM’s snowballing share price belies some other major Ash winners, and will make Christmas unhappy for funds that had shorted the stock.

Upcoming events – crucial cancer data for Tocagen and Syndax
Tocagen could soar or sink on interim brain cancer data, while judgement day approaches for Syndax.